46 results
Page 2 of 3
8-K
EX-99.1
v2p2tqrzz
8 Nov 21
Gossamer Bio Announces Third Quarter 2021 Financial Results and Provides Corporate Update
4:01pm
8-K
EX-99.1
zsi3 4ekqnrgx1qrjq0f
12 Oct 21
Regulation FD Disclosure
9:19am
8-K
EX-99.1
1hbdig gx
9 Aug 21
Gossamer Bio Announces Second Quarter 2021 Financial Results and Provides Corporate Update
4:27pm
8-K
EX-99.1
bdsfjm5o61y6375qdaa
6 May 21
Gossamer Bio Announces First Quarter 2021 Financial Results and Provides Corporate Update
8:06am
8-K
EX-99.1
m1u8o 4d6mbbjnnoq5
25 Feb 21
Gossamer Bio Announces Fourth Quarter and Full-Year 2020 Financial Results and Provides Business Update
8:00am
8-K
EX-99.1
lthvqhz52at
10 Nov 20
Gossamer Bio Announces Third Quarter 2020 Financial Results and Provides Corporate Update
4:14pm
8-K
EX-99.1
plyrgm8h m7bi
13 Oct 20
Gossamer Bio Announces Topline Results for Phase 2 Trials of Oral GB001 in Asthma and Chronic Rhinosinusitis
7:40am
8-K
dfl38e6
13 Oct 20
Gossamer Bio Announces Topline Results for Phase 2 Trials of Oral GB001 in Asthma and Chronic Rhinosinusitis
7:40am
8-K
EX-99.2
k5gwgsliobz6
13 Oct 20
Gossamer Bio Announces Topline Results for Phase 2 Trials of Oral GB001 in Asthma and Chronic Rhinosinusitis
7:40am
8-K
EX-99.1
ml019qsha4
11 Aug 20
Gossamer Bio Announces Second Quarter 2020 Financial Results and Provides Corporate Update
4:30pm
424B5
whg0fm 58nhgm
19 May 20
Prospectus supplement for primary offering
5:11pm
424B5
t2k73vajsfwg691p9
19 May 20
Prospectus supplement for primary offering
5:08pm
424B5
loz1er7i qn
18 May 20
Prospectus supplement for primary offering
4:16pm